An Evaluation Of Halozyme Therapeutics Inc. (NASDAQ: HALO) Prospects

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Earlier, Yahoo Finance discussed this stock as it revealed Halozyme to Participate in Upcoming Investor Conferences.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Stocks Info

HALO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Halozyme Therapeutics Inc. is $5.25B. A total of 0.81 million shares were traded on the day, compared to an average of 1.34M shares.

In the most recent transaction, LaBarre Michael J. sold 10,000 shares of HALO for 42.27 per share on Mar 13 ’24. After the transaction, the SVP, CHIEF TECHNICAL OFFICER now owns 156,558 company shares. In a previous transaction on Mar 12 ’24, LaBarre Michael J. sold 10,000 shares at 41.64 per share. HALO shares that SVP, CHIEF TECHNICAL OFFICER owns now total 156,558.

Among the insiders who sold shares, LaBarre Michael J. disposed of 10,000 shares on Feb 28 ’24 at a per-share price of $39.55. This resulted in the SVP, CHIEF TECHNICAL OFFICER holding 156,558 shares of HALO after the transaction. In another insider transaction, LaBarre Michael J. sold 10,000 shares at $39.95 per share on Feb 27 ’24. Company shares held by the SVP, CHIEF TECHNICAL OFFICER now total 159,087.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, HALO has a high of $45.00 and a low of $29.85.

As of this writing, HALO has an earnings estimate of $0.76 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $0.83 per share and a lower estimate of $0.69. The company reported an EPS of $0.75 in the last quarter, which was 5.60% higher than expectations of $0.71.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. HALO’s latest balance sheet shows that the firm has $740.92M in Cash & Short Term Investments as of fiscal 2021. There were $876.67M in debt and $117.15M in liabilities at the time. Its Book Value Per Share was $0.66, while its Total Shareholder’s Equity was $196.95M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for HALO is Buy with a score of 4.60.

Most Popular

Related Posts